For instance, baicalein, a novel toll-like receptor 4 (TLR4)-targeted therapeutic drug, inhibits the development of colorectal cancer (CRC) by inhibiting the TLR4/hypoxia-inducible factor-1/vascular endothelial growth factor signaling pathway (Chen et al., 2021). The gene discussed is TLR4; the disease is colorectal carcinoma.